One-liner#

Evaluate chronic dyspnea (weeks to months) systematically to identify the underlying cause—most commonly COPD, heart failure, asthma, or deconditioning—while recognizing interstitial lung disease and other less common but treatable conditions.

Quick nav#

• Red flags / send to ED
• Key history
• Focused exam
• Differential (quick pattern recognition)
• Workup
• Initial management
• Management by diagnosis
• Follow-up
• Patient instructions
• Smartphrase snippets

Red flags / send to ED#

• Acute worsening of chronic dyspnea with respiratory distress
• SpO₂ <88% on room air (or significant drop from baseline)
• New chest pain concerning for ACS or PE
• Syncope or presyncope with exertion
• Hemoptysis
• Stridor or signs of upper airway obstruction

Key history#

Characterize the dyspnea:

• Onset: gradual (COPD, ILD, HF) vs episodic (asthma)
• Duration: weeks, months, years
• Progression: stable, slowly progressive, rapidly progressive
• Triggers: exertion (most causes), allergens/irritants (asthma), lying flat (HF), cold air (asthma, COPD)
• Relieving factors: rest, bronchodilators, sitting upright

Quantify functional limitation (mMRC dyspnea scale):

Associated symptoms:

• Cough: productive (COPD, bronchiectasis), dry (ILD, HF)
• Wheezing: asthma, COPD, cardiac asthma
• Orthopnea/PND: HF (also severe COPD)
• Edema: HF, cor pulmonale
• Chest pain: cardiac disease, pulmonary HTN
• Fatigue: anemia, HF, deconditioning, depression
• Weight loss: malignancy, COPD (cachexia), ILD

Risk factors and exposures:

• Smoking: pack-years (COPD, lung cancer); current vs former
• Occupational: asbestos, silica, coal, organic dusts (ILD)
• Environmental: mold, birds (hypersensitivity pneumonitis)
• Medications: amiodarone, methotrexate, nitrofurantoin, bleomycin (drug-induced ILD)
• Autoimmune disease: RA, scleroderma, myositis (ILD)
• Radiation history: radiation pneumonitis/fibrosis

Cardiac history:

• Known HF, CAD, valvular disease
• Risk factors: HTN, DM, hyperlipidemia, obesity
• Prior cardiac testing

Other medical history:

• Anemia
• Obesity (obesity hypoventilation, deconditioning)
• Neuromuscular disease (diaphragm weakness)
• Anxiety/depression (may coexist or mimic)

Focused exam#

• Vitals: SpO₂ at rest AND with exertion (6-minute walk or walk around office), RR, HR, BP, BMI
• General: body habitus (cachexia, obesity), respiratory distress at rest, ability to speak in full sentences
• HEENT: nasal polyps (asthma with AERD), pallor (anemia)
• Neck: JVD (HF, cor pulmonale), tracheal position, thyromegaly
• Lungs:
  • Wheezes: asthma, COPD
  • Crackles: HF (bilateral, bases), ILD (bilateral, “velcro” crackles), bronchiectasis
  • Decreased breath sounds: COPD (hyperinflation), effusion
  • Prolonged expiration: obstructive disease
• Cardiac: displaced PMI (cardiomegaly), S3 (HF), loud P2 (pulmonary HTN), murmurs
• Abdomen: hepatomegaly, ascites (right heart failure)
• Extremities: clubbing (ILD, bronchiectasis, lung cancer), edema (HF, cor pulmonale), cyanosis
• Musculoskeletal: muscle wasting, kyphoscoliosis (restrictive)

Exertional desaturation:

• Check SpO₂ at rest, then after walking (6-minute walk test or walk around office)
• Desaturation ≥4% or to <88% with exertion is significant
• Suggests parenchymal lung disease, pulmonary vascular disease, or severe cardiac disease

Differential (quick pattern recognition)#

Common/likely (outpatient)#

Can’t-miss / urgent#

Workup#

Initial workup for all patients with chronic dyspnea:

Second-line workup based on initial findings:

When NOT to order:

• CT chest before CXR (unless high suspicion for malignancy or ILD)
• Echocardiogram in everyone (order if BNP elevated or cardiac cause suspected)
• CPET before basic workup (reserve for unexplained cases)

Initial management#

General approach:

1. Identify and treat the underlying cause
2. Optimize modifiable factors (smoking cessation, weight loss, exercise)
3. Symptomatic management while workup proceeds
4. Refer to specialist if diagnosis unclear or disease severe

Smoking cessation (if applicable):

• Most important intervention for COPD and lung cancer prevention
• Offer pharmacotherapy (varenicline, bupropion, NRT)
• Refer to smoking cessation program

Pulmonary rehabilitation:

• Indicated for COPD, ILD, and other chronic lung diseases
• Improves exercise tolerance, dyspnea, and quality of life
• Refer to pulmonary rehab program

Supplemental oxygen:

• Indicated if SpO₂ ≤88% at rest or with exertion
• Requires formal oxygen qualification (ABG or oximetry documentation)
• Pulmonology referral for oxygen prescription and titration

Home oxygen qualification criteria (Medicare):

• SpO₂ ≤88% at rest (or PaO₂ ≤55 mmHg), OR
• SpO₂ 89% at rest with evidence of cor pulmonale, RV failure, or erythrocytosis (Hct >56%), OR
• SpO₂ ≤88% during exercise or sleep (qualifies for oxygen during those activities)
• Must be documented on room air, at rest, in stable condition
• Requalification required at 90 days for new oxygen users

Management by diagnosis#

COPD#

Education:

• Chronic, progressive disease caused by smoking (usually)
• Smoking cessation is THE most important intervention
• Medications control symptoms and reduce exacerbations but don’t cure disease
• Vaccinations (influenza, pneumococcal, COVID, RSV) reduce exacerbation risk

Treatment (GOLD guidelines):

Initial therapy based on symptoms and exacerbation history:

• Group A (few symptoms, low exacerbation risk): SABA or SAMA PRN
• Group B (more symptoms, low exacerbation risk): LAMA or LABA
• Group E (any symptoms, high exacerbation risk): LAMA + LABA; add ICS if eosinophils ≥300

Triple therapy (LAMA + LABA + ICS):

• Indicated for patients with continued exacerbations on dual therapy and eosinophils ≥100
• Fluticasone/umeclidinium/vilanterol (Trelegy) 100/62.5/25 mcg daily
• Budesonide/glycopyrrolate/formoterol (Breztri) 160/18/9.6 mcg BID

Adjunctive therapies:

• Roflumilast (PDE4 inhibitor): for severe COPD with chronic bronchitis and frequent exacerbations
• Azithromycin 250 mg daily: reduces exacerbations in selected patients (pulmonology to initiate)

Follow-up: Reassess symptoms and exacerbations every 3–6 months. Annual spirometry. Pulmonology referral if FEV1 <50%, frequent exacerbations, or oxygen needed.

Asthma-COPD Overlap (ACO)#

Education:

• Features of both asthma and COPD in the same patient
• Typically: smoking history + airflow obstruction + significant bronchodilator response or eosinophilia
• Higher exacerbation risk than either condition alone

Treatment:

• ICS-LABA is first-line (unlike pure COPD where ICS is added later)
• Add LAMA for additional bronchodilation
• Avoid ICS monotherapy (LABA component important)
• Pulmonology referral recommended for management

Follow-up: Pulmonology co-management recommended given complexity.

Heart Failure#

Education:

• Heart not pumping effectively; fluid backs up into lungs and body
• Daily weights detect early fluid retention
• Sodium restriction (<2 g/day) and medication adherence are critical
• HFrEF (EF ≤40%) and HFpEF (EF >40%) have different treatments

Treatment (HFrEF - guideline-directed medical therapy):

HFpEF treatment:

• Diuretics for congestion
• SGLT2 inhibitors (dapagliflozin, empagliflozin) - mortality benefit
• Treat underlying conditions (HTN, AF, CAD)
• No proven benefit from ACEi/ARB, beta-blockers, or MRA (but often used)

Follow-up: Cardiology co-management. Reassess volume status, symptoms, and labs every 1–4 weeks during titration. Stable patients every 3–6 months.

Asthma#

Education:

• Chronic airway inflammation with reversible obstruction
• Triggers: allergens, infections, exercise, irritants
• Controller medications (ICS) reduce inflammation; rescue medications (SABA) treat acute symptoms
• Goal is symptom control with minimal rescue inhaler use

Treatment (stepwise approach):

Step 1 (intermittent):

• PRN low-dose ICS-formoterol (preferred) OR SABA PRN

Step 2 (mild persistent):

• Daily low-dose ICS + PRN SABA

Step 3 (moderate):

• Low-dose ICS-LABA + PRN SABA

Step 4 (moderate-severe):

• Medium-dose ICS-LABA + PRN SABA

Step 5 (severe):

• High-dose ICS-LABA; consider add-on (LAMA, biologic); pulmonology referral

Follow-up: Reassess control every 1–3 months. Step up if uncontrolled; step down after 3 months of good control. Pulmonology referral if step 4+ therapy needed.

Interstitial Lung Disease#

Education:

• Group of diseases causing scarring/inflammation of lung tissue
• Many causes: idiopathic (IPF), autoimmune (RA, scleroderma), occupational, drug-induced
• Progressive dyspnea and dry cough are typical
• Requires pulmonology for diagnosis and management

PCP role:

• Recognize clinical features (velcro crackles, clubbing, exertional desaturation)
• Order CXR → HRCT if suspicious
• Refer to pulmonology for diagnosis (may need bronchoscopy or surgical biopsy)
• Manage comorbidities; coordinate care

Treatment (pulmonology-directed):

• Antifibrotic therapy for IPF: pirfenidone, nintedanib (specialist-initiated)
• Immunosuppression for inflammatory ILD (autoimmune, HP): steroids, mycophenolate, azathioprine
• Supplemental oxygen if hypoxic
• Pulmonary rehabilitation
• Lung transplant evaluation for advanced disease

Follow-up: Pulmonology co-management. PCP monitors for medication side effects, manages comorbidities, coordinates care.

Pulmonary Hypertension#

Education:

• Elevated pressure in pulmonary arteries
• WHO Groups: 1 (PAH), 2 (left heart disease), 3 (lung disease), 4 (CTEPH), 5 (miscellaneous)
• Symptoms: exertional dyspnea, fatigue, syncope, edema
• Requires specialist evaluation and management

PCP role:

• Recognize clinical features (loud P2, RV heave, JVD, edema)
• Order echocardiogram (elevated RVSP suggests PH)
• Refer to pulmonology/cardiology (PH center if available)
• Treat underlying causes (OSA, COPD, left heart disease)

Treatment (specialist-directed):

• Group 1 (PAH): pulmonary vasodilators (sildenafil, tadalafil, endothelin receptor antagonists, prostacyclins)
• Group 2: optimize HF management
• Group 3: optimize lung disease management; supplemental O₂
• Group 4 (CTEPH): anticoagulation; consider pulmonary endarterectomy or riociguat

Follow-up: Specialist co-management. PCP manages comorbidities and monitors for medication side effects.

Deconditioning/Obesity#

Education:

• Dyspnea due to poor cardiovascular fitness and/or excess weight
• Diagnosis of exclusion—must rule out cardiac and pulmonary disease
• Gradual exercise program improves symptoms
• Weight loss (if obese) significantly improves dyspnea

Treatment:

• Structured exercise program: start low, progress gradually
• Goal: 150 minutes/week of moderate-intensity aerobic exercise
• Weight loss: dietary modification, consider GLP-1 agonists or bariatric surgery if BMI ≥35 with comorbidities
• Cardiac rehab referral if cardiac disease present

Follow-up: Reassess in 4–8 weeks. Monitor weight, exercise tolerance, and symptoms. If not improving, reconsider diagnosis.

Anemia#

Education:

• Reduced oxygen-carrying capacity causes dyspnea, especially with exertion
• Must identify and treat underlying cause (iron deficiency, B12/folate, chronic disease, blood loss)
• Symptoms improve as hemoglobin normalizes

Treatment:

• Treat underlying cause
• Iron deficiency: oral iron (ferrous sulfate 325 mg daily-TID) or IV iron if intolerant/malabsorptive
• B12 deficiency: cyanocobalamin 1000 mcg IM monthly or high-dose oral (1000–2000 mcg daily)
• Anemia of chronic disease: treat underlying condition; consider ESA if CKD
• Transfusion: rarely needed unless symptomatic and Hgb <7–8 g/dL

Follow-up: Recheck CBC in 4–8 weeks. Iron studies to confirm repletion. GI referral if iron deficiency without clear source.

Follow-up#

Default intervals:

• COPD: every 3–6 months; annual spirometry
• HF: every 1–4 weeks during titration; every 3–6 months when stable
• Asthma: every 1–3 months until controlled; every 3–6 months when stable
• ILD/PH: specialist-directed; PCP every 3–6 months for comorbidities

Referral thresholds:

• Pulmonology: ILD, pulmonary HTN, severe COPD (FEV1 <50%), unexplained dyspnea, oxygen evaluation
• Cardiology: HF (especially new diagnosis or decompensation), valvular disease, pulmonary HTN
• Hematology: unexplained anemia, suspected hematologic malignancy

Return precautions:

• Worsening shortness of breath
• New or worsening chest pain
• Swelling in legs getting worse
• Waking up at night unable to breathe
• Coughing up blood
• Feeling faint or passing out

Patient instructions#

• Chronic shortness of breath has many causes. We are working to find the cause and the best treatment for you.
• If you smoke, quitting is the single most important thing you can do for your breathing. We can help with medications and support.
• Take all medications as prescribed. Many breathing medications take time to work, so don’t stop them if you don’t feel immediate improvement.
• Stay as active as you can. Regular exercise, even walking, can improve your breathing over time.
• If you have heart failure, weigh yourself every morning and call the office if you gain more than 2–3 pounds in 1–2 days.
• Keep all follow-up appointments so we can monitor your progress and adjust treatment.
• Call the office or seek emergency care if your breathing suddenly gets much worse, you have chest pain, or you feel like you might pass out.

Smartphrase snippets#

.DYSPNEACHRONICWORKUP Chronic dyspnea evaluation. Spirometry shows [normal / obstructive pattern / restrictive pattern]. CXR [normal / shows X]. BNP [normal / elevated at X]. SpO₂ [X]% at rest, [X]% with exertion. Assessment: [likely diagnosis]. Plan: [treatment / further workup / referral]. Follow-up in [X weeks].

.DYSPNEACHRONICCOPD COPD, GOLD stage [I-IV], group [A/B/E]. FEV1 [X]% predicted. Current therapy: [list]. Symptoms [controlled / not controlled]. Plan: [continue current therapy / step up to X / add X]. Smoking cessation [discussed / patient quit X years ago]. Vaccinations up to date. Pulmonary rehab [referred / completed / declined]. Follow-up in [3–6 months].

.DYSPNEACHRONICHF Heart failure, [HFrEF EF X% / HFpEF EF X%]. NYHA class [I-IV]. Current GDMT: [list medications]. Volume status: [euvolemic / hypervolemic]. Plan: [continue current therapy / uptitrate X / add X / increase diuretic]. Daily weights and sodium restriction reinforced. Cardiology follow-up [scheduled / recommended]. PCP follow-up in [X weeks].

Related pages#

• Dyspnea (Acute) — acute shortness of breath evaluation
• Cough (Chronic) — chronic cough differential
• Wheeze — wheezing-focused evaluation
• Edema — peripheral edema differential
• COPD (problem) — chronic COPD management
• Asthma (problem) — chronic asthma management
• Obstructive Sleep Apnea (problem) — OSA diagnosis and CPAP management
• Heart Failure (problem) — chronic HF management
• Obesity (problem) — obesity management (coming soon)